Home / Business News (page 20)

Business News

Boehringer Ingelheim Acquires All Shares of ViraTherapeutics to Develop Next Generation Viral-Based Immuno-Oncology Therapies

INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim today announced that it has acquired all shares of ViraTherapeutics, a biopharmaceutical company specializing in the development of oncolytic viral therapies. ViraTherapeutics developed the lead candidate VSV-GP (Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP)), which is being investigated alone and in combination with other therapies. …

Read More »

Evolent Health to Expand its Specialty Care Management Capabilities through Acquisition of New Century Health

WASHINGTON, Sept. 12, 2018 /PRNewswire/ — Evolent Health, Inc. (NYSE : EVH ) – Evolent Health, Inc. (“Evolent”) and NCIS Holdings, Inc. and New Century Investment, LLC (“New Century Health”) announced today that they have entered into a definitive agreement for Evolent to acquire New Century Health’s business for up …

Read More »

Incyte and Foundation Medicine Partner to Develop Companion Diagnostic for Pemigatinib in Patients with Cholangiocarcinoma

WILMINGTON, Del. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Incyte Corporation (NASDAQ:INCY) and Foundation Medicine, Inc., today announced that the companies have entered into an agreement for the development, regulatory support and commercialization of companion diagnostics (CDx), with an initial focus on CDx development for pemigatinib (INCB54828), Incyte’s selective FGFR1/2/3 inhibitor, in patients with …

Read More »

After Phase 2 Failure, Pfizer Terminates Domagrozumab Program for Treatment of Duchenne Muscular Dystrophy

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) announced today that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD): a Phase 2 safety and efficacy study (B5161002) and an open-label extension study (B5161004). The Phase 2 study (B5161002), did not meet its …

Read More »

Ferring and Celmatix Partner to Advance Care in Reproductive Medicine and Accelerate Development of Personalized Interventions

SAINT-PREX, Switzerland & NEW YORK–(BUSINESS WIRE)–Ferring Pharmaceuticals and Celmatix today announced an ambitious genomics collaboration aimed at uncovering new insights into ovarian biology and accelerating the development of personalized interventions in reproductive medicine and women’s health. This collaboration will leverage both Ferring and Celmatix’s significant expertise in women’s reproductive health …

Read More »

Vertex and Genomics plc Collaborate to Use Human Genetics and Data Science to Advance Discovery of Precision Medicines

BOSTON & OXFORD, United Kingdom–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Genomics plc today announced a three-year collaboration, extendable to five years, to use human genetics and machine learning to improve discovery of targets for precision medicines, and to advance understanding of the clinical impact of human genetic variation and …

Read More »

ProLynx and Daiichi Sankyo Announce the Development of Technology for Half-Life Extension of Small Molecules in the Eye

SAN FRANCISCO, Aug. 29, 2018 (GLOBE NEWSWIRE) — ProLynx and Daiichi Sankyo Company, Limited, announced today the publication of a paper in the journal TVST entitled “A controlled release system for long-acting intravitreal delivery of small molecules”. In this work, they described a technology to extend the intravitreal half-life of …

Read More »

HTG Introduces the HTG EdgeSeq Mouse miRNA Whole Transcriptome Assay, a Comprehensive Panel for miRNA Expression Analysis for use in Translational Medicine and Preclinical Studies

TUCSON, Ariz., Aug. 29, 2018 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced the pre-launch introduction of the new HTG EdgeSeq Mouse miRNA Whole Transcriptome Assay (WTA) with product availability for shipment expected in the fourth …

Read More »

Genprex Amends Options to License Additional Cancer Fighting Technologies from MD Anderson Cancer Center

AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it has entered into amendments with The University of Texas MD Anderson Cancer Center (MD Anderson) to extend the …

Read More »

Horizon Discovery Announces Collaboration with Major Pharma Company on Single Cell RNAseq-Linked CRISPR Screening

CAMBRIDGE, England–(BUSINESS WIRE)–Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company”, or “the Group”), a global leader in gene editing and gene modulation technologies, today announces that is has entered into a collaboration with a global pharma partner to co-develop and apply a novel cutting-edge research tool for target identification …

Read More »